ProCE Banner Activity

Comprehensive COVID-19 Slideset: Special Populations and Comorbidities

Slideset Download
Comprehensive slideset updated regularly to include the latest data and guidance on COVID prevention and treatment in special populations and patients with certain comorbidities.

Released: August 08, 2022

Expiration: August 07, 2023

Share

Faculty

Arthur Kim

Arthur Kim, MD

Associate Professor of Medicine
Harvard Medical School
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Sharon R. Lewin

Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director, The Peter Doherty Institute for Infection and Immunity
Melbourne Laureate Professor and Head, Department of Infectious Disease
The University of Melbourne
Consultant Physician
Royal Melbourne and Alfred Hospitals
Melbourne, Australia

Kristen Marks

Kristen Marks, MD

Assistant Professor of Medicine
Division of Infectious Diseases
Weill Cornell Medicine
New York, New York

Renslow Sherer

Renslow Sherer, MD

Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Arthur Kim, MD

Associate Professor of Medicine
Harvard Medical School
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Arthur Kim, MD, has disclosed that he has served on the drug and safety monitoring board of Kintor Pharmaceuticals.

Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director, The Peter Doherty Institute for Infection and Immunity
Melbourne Laureate Professor and Head, Department of Infectious Disease
The University of Melbourne
Consultant Physician
Royal Melbourne and Alfred Hospitals
Melbourne, Australia

Sharon Lewin, AO, FRACP, PhD, FAAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.

Kristen Marks, MD

Assistant Professor of Medicine
Division of Infectious Diseases
Weill Cornell Medicine
New York, New York

Kristen Marks, MD, has disclosed that she has received funds for research support paid to Weill Cornell Medicine from Gilead Sciences.

Renslow Sherer, MD

Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois

Renslow Sherer, MD, has disclosed an unrestricted research grant from Gilead Sciences.